Plug Power CFO Paul Middleton Underscores Continued Confidence in Strategic Growth with Additional Share Purchase
LATHAM, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, today announced that Chief Financial Officer Paul Middleton has purchased an additional 650,000 shares of Plug's common stock on the open market. On June 9, 2025, Middleton acquired 650,000 shares at an average price of $1.0339 per share.
This latest investment follows a previous purchase earlier this month, reinforcing Mr. Middleton's continued belief in Plug's long-term strategy, strong financial trajectory, and leadership in building a vertically integrated hydrogen ecosystem.
'This additional investment reflects my strong conviction in Plug's strategy and long-term value creation. As we execute and gain market traction, I continue to see meaningful upside and believe Plug remains one of the most compelling growth opportunities in the energy sector.'
Middleton's open-market purchase underscores executive confidence in Plug's operational progress, including the ramp-up of hydrogen production plants, commercialization of GenEco electrolyzers, and growing demand for GenDrive fuel cell solutions across material handling and industrial markets.
'This is a transformative moment for our business and our industry. I believe deeply in Plug's ability to lead this energy transition—and I'm proud to continue investing in that future,' he added.
The purchase was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on June 9, 2025.
About Plug Power
Plug is building the global hydrogen economy with a fully integrated ecosystem spanning production, storage, delivery, and power generation. A first mover in the industry, Plug provides electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure to industries such as material handling, industrial applications, and energy producers—advancing energy independence and decarbonization at scale.
With electrolyzers deployed across five continents, Plug leads in hydrogen production, delivering large-scale projects that redefine industrial power. The company has deployed over 72,000 fuel cell systems and 275 fueling stations and is the largest user of liquid hydrogen. Plug is rapidly expanding its generation network to ensure reliable, domestically produced supply, with hydrogen plants currently operational in Georgia, Tennessee, and Louisiana, capable of producing 39 tons per day.
With employees and state-of-the-art manufacturing facilities across the globe, Plug powers global leaders like Walmart, Amazon, Home Depot, BMW, and BP.
Safe Harbor
This communication contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements about plans, goals, objectives, strategies, future events, expected results, beliefs, assumptions and any other statements that have not occurred. You are cautioned that such statements should not be read as a guarantee of future performance or results as such statements are subject to risks and uncertainties. Actual performance or results may differ materially from those expressed in these statements as a result of various factors, including, but not limited to, the following: the risk of elimination, nonrenewal, reduction of, or changes in qualifying criteria for government subsidies and economic incentives for alternative energy products, including the Inflation Reduction Act and its qualification to utilize the ITC; the anticipated benefits and actual savings and costs resulting from the implementation of cost-reduction measures; the risk that Plug's ability to achieve its business objectives and to continue to meet its obligations is dependent upon its ability to maintain a certain level of liquidity, which will depend in part on its ability to manage its cash flows; the risk that the funding of the Department of Energy loan may be delayed or cancelled; the risk that Plug may continue to incur losses and might never achieve or maintain profitability; the risk that Plug may not be successful in its financing initiatives and not have sufficient capital to continue its operations; the risk that Plug may not be able to expand its business or manage its future growth effectively; the risk that global economic uncertainty, including inflationary pressures, fluctuating interest rates, currency fluctuations, increase in tariffs, and supply chain disruptions, may adversely affect Plug's operating results; the risk that Plug may not be able to obtain from its hydrogen suppliers a sufficient supply of hydrogen at competitive prices or the risk that Plug may not be able to produce hydrogen internally at competitive prices; the risk that delays in or not completing its product and project development goals may adversely affect its revenue and profitability; the risk that its estimated future revenue may not be indicative of actual future revenue or profitability; the risk that volatility in commodity prices and product shortages may adversely affect Plug's gross margins and financial results; the risk that Plug may not be able to manufacture and market products on a profitable and large-scale commercial basis; and other risks relating to Plug's business that are described in Plug's public filings with the Securities and Exchange Commission, including the 'Risk Factors' section of Plug's Annual Report on Form 10-K for the year ended December 31, 2024, Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 as well as any subsequent filings. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made as of the date hereof and Plug disclaims any obligation to update forward-looking statements except as may be required by law.
MEDIA CONTACT
Teal Hoyos
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Pen Needles Market to Hit USD 3.08 Billion by 2030 with 9.2% CAGR
"Key players in this market are adopting several organic and inorganic growth strategies (such as product launches, agreements, collaborations, acquisitions, and expansions). Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland)" Browse 267 market data Tables and 71 Figures spread through 285 Pages and in-depth TOC on "Pen Needles Market by Type (Standard Pen Needles, Safety Pen Needles), Length (8mm, 5mm), Setting (Home Care Settings), Application (Glucagon-Like Peptide-1 Therapy), Mode of Purchase (Over the Counter Purchase, Online Purchase) - Global Forecast to 2030 The pen needles market valued at US$ 1.69 Billion in 2023, is forecasted to grow at a robust CAGR of 9.2%, reaching US$ 1.81 Billion in 2024 and an impressive US$ 3.08 Billion by 2030. The pen needles market has been segmented based on type, length, application, mode of purchase, setting and region. The key factors driving the market growth of the pen needles market include the rising incidence of chronic diseases, favourable reimbursements in certain countries, and decreasing prices of insulin formulations. Factors that provide opportunities for market players include the growing preference for biosimilar drugs, emerging economies to offer high-growth potential, and rising healthcare expenditure on diabetes. Supportive government regulations, such as rigorous safety standards by the US FDA and favourable reimbursement policies, are also expected to fuel the uptake of technologically advanced products. A combination of these factors is expected to facilitate the increased adoption of pen needles in healthcare systems. Browse in-depth TOC on ' Pen Needles Market' 200 - Tables 80 - Figures 300 - Pages In this report, the pen needles market has been segmented on the basis of type, length, application, mode of purchase, setting and region. The pen needles market is segmented into standard pen needles and safety pen needles on the basis of type. Standard pen needles are budget-friendly needles for insulin delivery, which explains their popularity in low-income markets and among the uninsured. These needles are simple and basic, which makes them easier to manufacture. There is no requirement for ultra-thin design or sophisticated coating that is required for more expensive options. Cost is a major determinant in healthcare in developing nations and low-income brackets. With standard pen needles, accessible options for diabetic patients who need insulin therapy are readily available without worry of financial suffocation. Moreover, for the Grey market practioners in developed countries where people do not have insurance, these needles are a cheap and functional alternative. Thus, standard pen needles are vital because they meet minimum requirements of diabetes control which helps increase the availability of insulin delivery worldwide. The pen needles market is segmented into prescription-based, over the counter (OTC) purchase, online purchase and other modes of purchase on the basis of mode of purchase. Online purchase segment is expected to grow at the highest CAGR during the forecast period of the global pen needles market. As e-commerce grows across the world, the demand for pen needles is also on the rise as new customers are drawn to online shopping. Marketplaces make purchase easier for patients who can now shop for pen needles among other products while sitting in their homes. This is particularly helpful for people with movement disabilities or people living in far flung areas who don't have a ready access to local pharmacies. Businesses engaged in diabetes care and treatment are benefiting enormously as most e-commerce websites offer better rates, promotions, and subscriptions which aid in controlling diabetes. Furthermore, aspects like covert packaging and home delivery make e-commerce users feel more secure and comfortable. The vast variety of products and brands available in these platforms allows customers more purchasing freedom, which aids in increasing their adoption. The pen needles market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa and GCC Countries on the basis of geographic region. North America holds the largest share of the pen needles market in 2024. North America sees one of the maximum diabetes prevalence rates of the world with the U.S and Canada heads in the top of the insulin-dependent population. As per CDC, more than 37 million Americans suffer from diabetes, and approximately 1.6 million have type 1 diabetes. Thus, Canada also bears a huge burden of diabetes cases with an estimated total of 11.7 million that are affected by diabetes or prediabetes. The prevalence of such patients is relatively high, thus increasing demand for pen needles since it's the basic need for managing blood glucose. Pen needles require good infrastructure and wide awareness in place with patients desiring easy-to-handle devices such as pen needles, thereby augmenting the uptake of this equipment. Increased concern regarding proper management of diabetes helps in sustaining the demand in the region. Prominent players in this market include Embecta Corp. (US), Novo Nordisk A/S (Denmark), Ypsomed AG (Switzerland), B. Braun SE (Germany), Owen Mumford (UK), Terumo Corporation (Japan), NIPRO Corporation (Japan), Allison Medical, Inc. (US), AdvaCare Pharma (US), Berpu Medical Technology Co., Ltd. (China), ARKRAY, Inc. (Japan), GlucoRx Limited (UK), HTL-STREFA (Poland), UltiMed, Inc. (US), Hindustan Syringes and Medical Devices (India), Artsana Group (Italy), PromiseMed Medical Devices Inc. (Canada), Montmed, Inc. (Canada), Trividia Health, Inc. (US), VOGT Medical Vertrieb GmbH (Germany), Van Heek Medical (Netherlands), Simple Diagnostics (US), IYON Medical (Turkey), Links Medical Products, Inc. (US), and MHC Medical Products, LLC (US). EMBECTA CORP. (US) One of the main products traded by Embecta in the global market is pen needles. The company operates from a US-based facility, as well as having production plants in Ireland and China. The company's vast range of pen needles, syringes, and safety injection devices is a fundamental factor that helps it withstand competition in global market. Alongside the standard pen needles, the company has a safety pen needle portfolio. The company approaches the growth by both inorganic and organic mechanisms to cement its position in the pen needle market. For instance, on November 2022, Embecta Corporation (US) signed a agreement with Intuity Medical, Inc. (US) under which Embecta sales representatives in the US will promote Intuity Medical's high-tech POGO automatic blood glucose monitoring system to healthcare professionals. NOVO NORDISK A/S (DENMARK) The major source of revenue for the company is its Diabetes and Obesity Care segment. The global diabetes market provides an opportunity for the firm to generate revenues through its Diabetes Care segment. The company obtained approximately 40 million diabetic patients in 2022, from 32 million in Nordisk is well poised in production with ~16 production sites across five regions and a growing product portfolio, including pen needles. The R&D centers of the company are set up in China, Denmark, India, the UK, and the US. Novo Nordisk increased R&D investments from 13.6% in 2022 to 14.0% in 2023. The company also announced that it would be expanding its presence in the pen needles market through a research hub in the greater Boston metro area, which was announced in March 2023. B. BRAUN SE (GERMANY) B. Braun SE is another major player of the pen needle market. In terms of product, the group has a comprehensive presence across geographical boundaries. Also, it has recognition for its branded products, notably Omnican Fine and Omnican Fine Plus injection pen needles. The innovations included in the products such as three facet grinding tip and silicone coating or thin-wall technologies used for injecting pen needles will help the firm obtain a strong presence in branding at the overall markets. The company has a huge geographical presence and subsidiaries in 64 countries. Therefore, it is not dependent on a single market, thus sustaining its leading position. The company intends to focus on new technology and digital transformation for healthcare medical devices. For more information, Inquire Now!
Globe and Mail
2 hours ago
- Globe and Mail
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company's board of directors. 'Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,' said Paul Clancy, chair of the board of directors of Xilio Therapeutics. 'With over 25 years of experience in oncology research and development, focused on translational medicine and clinical pharmacology at BMS and Pfizer, we look forward to benefitting from Tunde's extensive expertise as we advance toward the clinic with XTX501, our masked PD-1/IL-2 bi-specific, and our bi-specific and tri-specific masked T cell engager programs.' 'Xilio's innovative approach to developing tumor-activated immuno-oncology therapies presents an exciting opportunity to advance novel molecules, which hold the potential to overcome the limitations of current cancer treatments,' said Dr. Bello. 'I am honored to join Xilio's board of directors at this important time and look forward to contributing to Xilio's efforts to meaningfully improve outcomes for patients while minimizing systemic toxicities.' Akintunde Bello, Ph.D. Dr. Bello brings more than 25 years of oncology drug development and leadership experience to Xilio, with deep expertise in early translational medicine and clinical pharmacology across complex biologics and immunotherapies, including anti-CTLA-4 and PD-1 checkpoint inhibitors, T cell engagers and tumor-selective molecules. He most recently served as senior vice president, head of clinical pharmacology, pharmacometrics and bioanalysis at Bristol Myers Squibb Company (BMS) until his retirement in 2025. While at BMS, Dr. Bello oversaw clinical pharmacology and pharmacometrics across multiple therapeutic areas. Prior to BMS, Dr. Bello spent more than a decade with Pfizer Inc. (Pfizer), where he was responsible for overseeing clinical pharmacology for Pfizer's late-stage oncology development programs. Dr. Bello received a in biomedical sciences from Portsmouth Polytechnic, an in instrumentation and analytical science from University of Manchester and a Ph.D. in pharmaceutical sciences from King's College, University of London. About Xilio Therapeutics Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting and follow us on LinkedIn (Xilio Therapeutics, Inc). Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding achievement of key milestones; and the potential benefits of any of Xilio's current or future product candidates in treating patients; and Xilio's strategy, goals, business plans and focus. The words 'aim,' 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'seek,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of important risks, uncertainties and other factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, general market conditions; risks and uncertainties related to ongoing and planned research and development activities, including initiating, conducting or completing preclinical studies and clinical trials and the timing and results of such preclinical studies or clinical trials; the delay of any current or planned preclinical studies or clinical trials or the development of Xilio's current or future product candidates; Xilio's ability to obtain and maintain sufficient preclinical and clinical supply of current or future product candidates; Xilio's advancement of multiple early-stage immune cell engager programs; interim or preliminary preclinical or clinical data or results, which may not be replicated in or predictive of future preclinical or clinical data or results; Xilio's ability to successfully demonstrate the safety and efficacy of its product candidates and gain approval of its product candidates on a timely basis, if at all; results from preclinical studies or clinical trials for Xilio's product candidates, which may not support further development of such product candidates; actions of regulatory agencies, which may affect the initiation, timing and progress of current or future clinical trials; Xilio's ability to obtain, maintain and enforce patent and other intellectual property protection for current or future product candidates; Xilio's ability to obtain and maintain sufficient cash resources to fund its operations; the impact of international trade policies on Xilio's business, including U.S. and China trade policies; Xilio's ability to maintain its clinical trial collaboration with Roche to develop vilastobart in combination with atezolizumab; and Xilio's ability to maintain its collaboration and partnership agreements with Gilead and AbbVie. These and other risks and uncertainties are described in greater detail in the sections entitled 'Risk Factor Summary' and 'Risk Factors' in Xilio's filings with the U.S. Securities and Exchange Commission (SEC), including Xilio's most recent Quarterly Report on Form 10-Q and any other filings that Xilio has made or may make with the SEC in the future. Any forward-looking statements contained in this press release represent Xilio's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Xilio explicitly disclaims any obligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Globe and Mail
2 hours ago
- Globe and Mail
Cohere launches AI health care agents in the U.S.
Canadian artificial intelligence company Cohere Inc. is entering the health care industry through a partnership with U.S.-based Ensemble Health Partners that uses AI agents to help hospitals and other providers manage their revenue. Cohere, founded in 2019, uses large-language models to build chatbots and generative-AI platforms for enterprise customers to automate some tasks. The partnership with Ensemble, launched Tuesday, uses a customized version of the North by Cohere platform that will run on health care providers' internal systems and help with tasks such as hospitals appealing insurance-claim denials and chasing down accounts receivable. The company said pre-launch tests of the tools accelerated denial appeals by 40 per cent and improved denial overturn rates by 15 per cent. Running on internal systems is a key part of how the AI system protects the safety of patients' information and complies with privacy law, said Cohere co-founder Ivan Zhang. 'There's no data leaving their system, because all the agents are in the house,' he said. Because of those privacy concerns, Mr. Zhang said the AI has to be trained on synthetic data, which would be similar to real-world data in likeness and structure but without any protected personal information. The foray into health-care follows Cohere's work in the financial sector, which has to adhere to similar privacy rules. In January, the company announced a partnership with Royal Bank of Canada to co-develop and run a customized platform called North for Banking which, among other things, helps employees answer questions from customers. Mr. Zhang said Cohere is focused on the U.S. market for now, but hopes to have more to announce for Canadian health-care soon. 'So far, we are focused on the U.S. markets. We want to take these learnings and adapt it to different systems in Canada and globally,' he said. Cohere did not disclose any financial terms or which U.S. clients are using the AI platform. The company also received a nod Tuesday from new federal AI minister Evan Solomon. In a speech in Ottawa, Mr. Solomon outlined the government's new approach to AI, saying it would shift from 'warnings and regulation' to celebrating industry 'champions' such as Cohere. Mr. Zhang said he was 'delighted' by the support and said there was a strong case to be made that investments in AI were part of strengthening Canada's economy and security. 'We've been very happy about the government's engagement so far,' he said.
